Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shanghai Pharma Signs MOU to Run China Phase III Trial of Korean Alzheimer’s Drug

publication date: Sep 14, 2023

Shanghai Pharmaceuticals signed an MOU with Korea’s AriBio to jointly conduct the China arm of a global Phase III trial of a therapy for mild Alzheimer’s disease. AriBio’s AR1001 is a selective inhibitor of phosphodiesterase 5 (PDE5) that is designed to inhibit neuron apoptosis and restore synaptic plasticity. If the drug is approved, Shanghai Pharma will have distribution and manufacturing rights for the candidate in China. In a Phase II trial, AR1001 was safe, and it showed efficacy, especially if patients were not taking other Alzheimer's medications, such as Aricept. More details....

Stock Symbols: (SHA: 601607; HK: 2607)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China